Results 261 to 270 of about 193,929 (276)
Some of the next articles are maybe not open access.
Modeling cytokine release syndrome
Nature Medicine, 2018Complete leukemic responses to chimeric antigen receptor–modified T cells are invariably accompanied by severe toxicity. Recently developed animal models allow mechanistic dissection and prevention of toxicity without loss of therapeutic benefit.
Cliona, Rooney, Tim, Sauer
openaire +2 more sources
Monoclonal antibody-induced cytokine-release syndrome
Expert Review of Clinical Immunology, 2009Monoclonal antibodies (mAbs) are widely used in anti-inflammatory and tumor therapy. Although effective, mAbs can cause a variety of adverse effects. An important toxicity seen with a few mAbs is cytokine-release syndrome (CRS). These mAbs include: alemtuzumab, muromonab-CD3, rituximab, tosituzumab, CP-870,893, LO-CD2a/BTI-322 and TGN1412. By contrast,
Peter J, Bugelski +4 more
openaire +2 more sources
Towards Remote Continuous Monitoring of Cytokine Release Syndrome
2022 44th Annual International Conference of the IEEE Engineering in Medicine & Biology Society (EMBC), 2022Cytokine release syndrome (CRS) is a noninfec-tious systemic inflammatory response syndrome condition and a principle severe adverse event common in oncology patients treated with immunotherapies. Accurate monitoring and timely prediction of CRS severity remain a challenge. This study presents an XGBoost-based machine learning algorithm for forecasting
Michael J, Pettinati +4 more
openaire +2 more sources
Management Principles Associated With Cytokine Release Syndrome
Seminars in Oncology Nursing, 2019To discuss current recommendations and resources for nurses to ensure they advocate for patients with cytokine release syndrome (CRS).A literature search using key terms: cytokine release syndrome, neurotoxicity, CAR T, adverse events.Chimeric antigen receptor (CAR) T-cell immunotherapy is a growing and rapidly changing field of research.
Brittney, Baer +2 more
openaire +2 more sources
Extracorporeal cytokine adsorption for treating severe refractory cytokine release syndrome (CRS)
Bone Marrow Transplantation, 2020International ...
Wallet, Florent +7 more
openaire +3 more sources
Extracorporeal cytokine removal in severe CAR-T cell associated cytokine release syndrome
Journal of Critical Care, 2020Life-threatening complications of CD-19 Chimeric antigen receptor - T (CAR-T) cells such as the cytokine release syndrome (CRS)) have been reported. Treatment is limited to IL-6 blockade and steroids although global removal of elevated soluble inflammatory factors might be more effective.Clinical course of a CRS patient treated with extracorporeal ...
Klaus, Stahl +11 more
openaire +2 more sources
Cytokine-Release Syndrome: Overview and Nursing Implications
Clinical Journal of Oncology Nursing, 2007Cytokine-release syndrome is a symptom complex associated with the use of many monoclonal antibodies. Commonly referred to as an infusion reaction, it results from the release of cytokines from cells targeted by the antibody as well as immune effector cells recruited to the area.
openaire +2 more sources
Cytokine release syndrome: a primer for generalists
Adverse Drug Reaction Bulletin, 2019Summary Cytokine release syndrome (CRS) is an adverse drug reaction that is poorly understood but is likely to be increasingly common as more immunotherapeutics are being developed and licensed, principally in the treatment of cancer.
Tiago Soares, Henry Fok
openaire +1 more source
Cytokine Release Syndrome and Sepsis
Infectious Disease Clinics of North America, 2022Janhavi Athale +2 more
openaire +1 more source
Understanding cytokine release syndrome
Intensive Care Medicine, 2017Philipp Gödel +2 more
openaire +2 more sources